detrusor overactivity

detrusor overactivity

involuntary contractions of the detrusor urinae muscle from any cause. Also called detrusor hyperactivity, detrusor hyperreflexia.
References in periodicals archive ?
Your doctor will want to monitor you for any breathing problems during your treatment with BOTOX for detrusor overactivity associated with a neurologic condition.
Examples of such pre-operative comorbidities include pre-existing voiding dysfunction such as ISD (18), (19) or neurogenic detrusor overactivity, as in Parkinson's disease or spinal cord injury.
Amundsen and her colleagues had expected to find notably lower nighttime urinary volumes in the participants with detrusor overactivity because of a greater voiding frequency.
Women were excluded if they had detrusor overactivity or previous sling surgery.
Additionally, oxybutynin is indicated in the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with neurological conditions (i.
org) recruited patients with refractory urge urinary incontinence and urodynamic evidence of detrusor overactivity incontinence (DOI) to a 2:1 placebo controlled cystoscopic injection of botulinum toxin A.
It appears, however, that detrusor contractility bladder capacity, and the ability to withhold voiding decline in both sexes; the maximal urethral closure pressure and length probably decline in women; detrusor overactivity increases in prevalence; and the post voiding residual (PVR) urine volume probably increases to 50 mL to 100 mL.
Your doctor will want to monitor you for any breathing problems during your treatment with BOTOX[R] for upper limb spasticity or for detrusor overactivity associated with a neurologic condition.
The factors analyzed to determine association with acute urinary retention or the inability to voluntarily pass urine included age, gender, diagnosis of diabetes, baseline post void residual presence of urodynamic detrusor overactivity, bladder capacity, peak flow rate and BTX-A dose.
is pleased to announce that BOTOX has been licensed by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the management of urinary incontinence in adult patients with neurogenic detrusor overactivity (NDO) due to subcervical spinal cord injury (SCI)(traumatic or non-traumatic) or multiple sclerosis (MS), who are not adequately managed with anticholinergics[sup.
Significant decrease in maximum detrusor pressure and increase in bladder compliance had been demonstrated in SCI patients with detrusor overactivity by furosemide-stimulated filling cystometry (FCMG), which is a more physiologic method when compared with continuous CMG with a filling rate of 50 ml/min (1).